- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07587359
A Unique, Co-Designed Family-Based Therapy
A Unique, Co-Designed Family-Based Therapy for Women With Opioid Use Disorder and Justice-Involvement
The goal of this pilot trial is to evaluate the feasibility and acceptability of an adapted MDFT intervention with women who report prior OUD and sex trade involvement participating in specialty court treatment programs. The main question[s] the trial aims to answer are:
- Will the inclusion of the adapted MDFT intervention be feasible among the target population?
- Will participant dyads assigned to the adapted intervention perceive the intervention as acceptable and beneficial?
Participants will be randomly assigned to receive either: 1) the adapted MDFT + TAU; or 2) TAU. Participants will complete baseline and post-intervention assessments.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sandy Solove
- Phone Number: 614-247-8366
- Email: solove.3@osu.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
Contact:
- Sandy Solove
- Phone Number: 614-247-8366
- Email: solove.3@osu.edu
-
Principal Investigator:
- Aaron Murnan, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria for Specialty Treatment Court Participants:
- 18 years of age or older
- Identify as a woman
- meet or have met DSM5 criteria for an Opioid Use Disorder (OUD)
- report current or prior sex trade involvement
- attending a specialty treatment court / treatment diversion program
- Identify one family member able to participate
Inclusion Criteria for Family Participants
- 18 years of age or older
- Willing to participate in a hypothetical family intervention
Exclusion Criteria for Specialty Treatment Court Participants:
- Under age 18
- Non-English speaking
Exclusion Criteria for Family Participants:
- Under age 18
- Non-English Speaking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Adapted MDFT + TAU
Participant dyads in this arm will receive up to 20 sessions of the adapted Multi-Dimensional Family Therapy (MDFT) intervention in addition to services received as part of their treatment as usual (TAU) received as part of their specialty treatment court program.
|
The adapted MDFT will be delivered during a 12 week period (max of 20 sessions).
The adapted MDFT seeks to support reductions in opioid use by targeting improvements in family factors (e.g.
family conflict/stress, support, functioning, and familial substance use) that relate closely to substance use and treatment outcomes.
Participant dyads come together to navigate and problem-solve family-level challenges.
In session, participants will learn new ways to communicate, receive support to mend damaged relationships, build trust, and ultimately develop new strategies of supporting one another's needs with emphasis on supporting women's reductions in substance use.
Interventionists work with family dyads to address problems underlying familial stress, conflict, and low support as they arise.
Successful strategies to navigate these challenges in session are then translated to outside of sessions to promote self-sustaining changes within families.
Specialty Treatment Court services include individual and group therapy sessions focused on substance use and mental health, case management, and wrap-around services related to housing and basic needs.
|
|
Active Comparator: Treatment As Uusual
This arm receives the normal services offered through the specialty court treatment program they are currently enrolled in.
This typically includes individual and group therapy sessions focused on substance use and mental health, case management, and wrap-around services related to housing and basic needs.
|
Specialty Treatment Court services include individual and group therapy sessions focused on substance use and mental health, case management, and wrap-around services related to housing and basic needs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention Feasibility
Time Frame: up to 3 months post-intervention
|
Feasibility will be assessed using rates of intervention engagement/utilization, among participating dyads.
Intervention engagement will be measured by the number of sessions attended by participants assigned to the adapted MDFT intervention.
Number of sessions utilized will range from 0-20, a higher number of sessions utilized will reflect better treatment engagement.
Participants who receive 4 or more sessions will be considered to have engaged in the intervention.
|
up to 3 months post-intervention
|
|
Client Satisfaction Questionnaire 8
Time Frame: up to 3 months post-intervention
|
The CSQ-8 consists of 8 questions that assess intervention recipient's satisfaction with the intervention they received.
The questions are scored on 4-point Likert scales, range of scores is 1-32 with higher scores reflecting higher satisfaction with the intervention.
|
up to 3 months post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Family Assessment Device (FAD-12)
Time Frame: 1) Baseline and 2) up to 3 months post-intervention
|
The Family Assessment Device will be administered to all participants and will yield data on various domains of family functioning across the family system.
The FAD-12, is a 12 self-report item measure that yields psychometrically validated subscale scores for: Involvement; responsiveness; behavioral control; communication; problem solving; and roles, which generates a psychometrically supported composite score for family functioning.
Questions are scored on a Likert Scale (1-4) with lower scores reflecting better family functioning and better outcomes.
Range of scores is 12-48.
|
1) Baseline and 2) up to 3 months post-intervention
|
|
Family Environment Scale
Time Frame: 1) Baseline and 2) up to 3 months post-intervention
|
The Family Environment Scale will yield scores for family conflict, cohesion, expressiveness, and quality of family relationships.
It will be administered to all participants as part of the pre and post-intervention assessment battery.
This measure uses True/False questions about participant's family environment to generate psychometrically validated scores for family conflict, cohesion, and quality of family relationships.
Raw total scores range from 0-90.
Results are interpreted by comparing individual raw scores to established normative reference ranges, typically expressed as standard T-scores with a mean of 50 and a standard deviation of 10.
Scores above or below 1 standard deviation from the mean suggest significant deviation in family dimensions.
Therefore higher scores suggest worse family environments and worse outcomes.
|
1) Baseline and 2) up to 3 months post-intervention
|
|
Perceived Social Support - Family Assessment (PSS-FA)
Time Frame: 1) Baseline and 2) up to 3 months post-intervention.
|
The Perceived Social Support - Family Assessment (PSS-FA) will be administered to assess family support at each time point.
The PSS-FA includes 20 self-report items (Yes[1]/No[0]) that yield a psychometrically validated subscale score for Family Support (range: 0-20), with higher scores reflecting higher levels of perceived support and better outcomes.
|
1) Baseline and 2) up to 3 months post-intervention.
|
|
Addiction Severity Index (ASI)
Time Frame: 1) Baseline and 2) up to 3 months post intervention.
|
Addiction Severity Index will be used to assess substance use among participants at both timepoints.
ASI is a clinical/research instrument.
Participants will be asked to answer questions related to the last 30 days including: days in treatment and days using various substances.
Increased number of days (0-30) of reported substance use will reflect worse substance use.
|
1) Baseline and 2) up to 3 months post intervention.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck Depression Inventory (BDI)
Time Frame: 1) Baseline and 2) up to 3 months post-intervention.
|
Beck Depression Inventory will be used to assess depressive symptoms among women and their family supports at both timepoints.
The BDI is a 21 question, self-report measure containing 21 Likert scale response questions (0-3), with higher scores reflecting worse depressive symptoms and outcomes.
Range of scores is 0-63.
|
1) Baseline and 2) up to 3 months post-intervention.
|
|
Beck Anxiety Inventory (BAI)
Time Frame: 1) Baseline and 2) up to 3 months post-intervention.
|
Beck Anxiety Inventory will be used to assess anxiety symptoms among women and their family supports at both timepoints.
The BAI includes 21 self-report items measured on a Likert scale (0-3), with higher scores reflecting worse anxiety symptoms and outcomes.
Range of scores is 0-63.
|
1) Baseline and 2) up to 3 months post-intervention.
|
|
Specialty Treatment Court Program Engagement
Time Frame: Up to 3 months post-intervention.
|
Details related to substance use treatment services received, mental health services received, and continuation of specialty court treatment programming will be monitored.
Engagement in specialty treatment court program will be assessed via lower rates of specialty court drop-out and higher service utilization.
Specifically, participants who utilize more services and who do not drop out of the program will be considered to being engaging more in their existing specialty treatment court programming.
|
Up to 3 months post-intervention.
|
|
Substance Use Stigma Mechanism Scale (SU-SMS)
Time Frame: 1) Baseline and 2) up to 3 months post-intervention.
|
The Substance Use Stigma Mechanism Scale (SU-SMS) will yield scores for perceived and experienced stigma related to substance use and substance use treatment.
It will be administered to participants as post of the pre and post-intervention assessment battery.
The measure uses 5-point Likert Scale questions to generate psychometrically validated scores for perceived stigma experienced.
Scores range from 0-90 with higher scores reflecting more perceived stigma experienced.
|
1) Baseline and 2) up to 3 months post-intervention.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Aaron W Murnan, PhD, Ohio State University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20251206
- K23DA058053 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Abuse (Disorder)
-
Kaiser PermanenteNational Institute on Drug Abuse (NIDA)CompletedOpioid Use Disorder | Substance Use Disorders | Substance Abuse | Opioid Abuse | Drug Abuse | Drug Use Disorders | Cannabis Abuse | Cannabis-Related Disorder
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)RecruitingOpioid Use Disorder | Opioid Withdrawal | Polysubstance Abuse | Opioid Abuse or Dependence | Polysubstance Drug Use (Indiscriminate Drug Use)Canada
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA)CompletedOpioid Abuse (Disorder)United States
-
Bubba NicholsonTampa General Hospital; Otrimed Clinical ResearchUnknownOpioid-Related Disorders | Opioid Dependence | Opioid Use | Opioid Abuse | Opioid-use Disorder | Opioid Addiction | Opioid Intoxication | Opioid Abuse, Continuous Use | Paternal Pheromone Deficiency | Opioid Abuse, Episodic
-
Clemson UniversityPrisma Health-UpstateCompletedAlcohol Use Disorder | Opioid-use Disorder | Opioid Abuse, in Remission | Alcohol Use Disorder, in RemissionUnited States
-
MindLight, LLCHarvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaboratorsCompletedOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
University of MinnesotaRecruitingOpioid Dependence | Opioid Abuse | Opioid-use DisorderUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)CompletedDepression | Opioid Abuse | Opioid-use DisorderUnited States
-
Milton S. Hershey Medical CenterNational Institute on Drug Abuse (NIDA); University of Maryland; New York UniversityRecruitingSubstance-Related Disorders | Chemically-Induced Disorders | Narcotic-Related Disorders | Opioid Use Disorder | Mental Disorder | Opioid | Opioid Abuse and AddictionUnited States
Clinical Trials on Adapted Multi-Dimensional Family Therapy
-
Gina DimitropoulosUniversity Health Network, TorontoCompleted
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); American Academy of Child Adolescent...CompletedCoping Skills | Family RelationshipUnited States
-
Hong Kong University of Science and TechnologyNot yet recruitingDementia | Alzheimer Disease | Mental Health | Sleepiness
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinCompleted
-
University of MichiganNational Institute of Mental Health (NIMH)RecruitingDepression | Anxiety | Drug Use | Racial Disparities | Minority Stress | Family Relationships | LGBTQ | Teen Dating Violence | Sexual Risk ReductionUnited States
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
University of Illinois at ChicagoBlue Cross Blue ShieldActive, not recruiting
-
University of OregonNational Institute on Drug Abuse (NIDA)Recruiting
-
University of BaselNational Cancer Center, Korea; University Hospital, Geneva; Swiss National Science... and other collaboratorsCompletedBreast Cancer | Ovarian Cancer | Hereditary CancerSwitzerland
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH); Annie E. Casey FoundationCompleted